# InnoSIGN

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innosign-b-v

- Industry: Biotechnology
- Headquarters: Eindhoven, Netherlands
- Website: www.innosignbio.com
- Total disclosed funding: $8M
- Latest round: Series A (Mar 22, 2022)
- Investors on record: 4

## About

Based in Eindhoven, Netherlands, and founded in 2022, InnoSIGN B.V. is a precision medicine firm that focuses on diagnostics and drug development applications. It is a spin-out from Koninklijke Philips N.V. In March 2022, InnoSIGN B.V. raised USD 8 million in Series A funding from Brabant Development Agency BOM, Casdin Capital, Life Science Angels, Inc., and Thuja Capital. Paul van de Wiel is the CEO of the company.

The company provides OncoSIGNal pathway activity profiling technology, which is based on mRNA, which is transforming precision medicine by providing additional insight into disease causes.  The firm utilizes its database with more than 100,000 pathway activity profiles to support diagnostics and drug development.

The March 2022 investment supports the organization's clinical validation and US market launch.

## Funding rounds

- Series A, Mar 22, 2022, $8M — Thuja Capital, Life Science Angels, Inc., Casdin Capital, BOM Brabant Ventures

## Investors

- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Series A
- Life Science Angels, Inc. — Series A
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A
- BOM Brabant Ventures (https://capitalatlas.ai/funds/bom-brabant-ventures) — Series A